The　abnormal　aggregation　of　Aβ　has　been　considered　one　of　the　primary　causative　factors　for　Alzheimer＇s　disease.　Diverse　molecular　entities　have　been　developed　to　mitigate　the　formation　of　toxic　Aβ　aggregates　within　the　brain　by　inhibiting　Aβ　aggregation.　Recognizing　that　many　FDA-approved　drugs　are　derived　from　natural　products,　we　present　a　summary　of　recent　discoveries　involving　natural　product　molecules　with　inhibitory　effects　on　Aβ　aggregation.　By　consolidating　these　findings,　our　review　offers　researchers　a　concise　overview　of　the　latest　advancements　in　natural　product-based　interventions　for　Alzheimer＇s　disease.　©　2024　Wiley-VCH　GmbH.